Pfizer's decision to announce a deal with the Trump administration on drug prices Tuesday caused an uproar within much of the pharmaceutical industry, most of which was caught off guard by the ...
Pfizer is getting into the obesity treatment industry with a multi-billion-dollar deal for Mestera. Currently, Pfizer and Mestera don’t have an obesity drug on the market. The deal between the two ...
President Donald Trump on Tuesday announced the creation of “TrumpRx,” a direct-to-consumer website where customers can buy drugs directly, as well as an agreement with pharmaceutical manufacturer ...
Pfizer (PFE) CEO and chairman Albert Bourla told Yahoo Finance Executive Editor Brian Sozzi during Yahoo Finance's annual Investconference that the $10 billion acquisition of GLP-1 maker Metsera (MTSR ...
Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...
Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump ...
Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...
(Reuters) -Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold in the fast-growing obesity market following a fierce bidding ...
Oct 31 (Reuters) - U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback